Compare Incyte Corporation (INCY) vs Public Storage (PSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Public Storage — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Public Storage trades at $290.28 (market cap $53.35B). The key difference: Public Storage is far larger — about 2.3× Incyte Corporation's market cap, and Public Storage pays a 4.2% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Public Storage for 130 Days on average.
| INCY | PSA | |
|---|---|---|
Market Cap | $22.85B | $53.35B |
Volume | 1,927,029 | 1,176,034 |
Sector | Health | Real Estate |
52-Week High | $129.93 | $330.47 |
52-Week Low | $83.80 | $258.44 |
Typical Hold Time | 33 Days | 130 Days |
Enterprise Value | $18.35B | $67.62B |
Dividend Yield | — | 4.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Public Storage (PSA) trades at $287.72, up 2.03% today, with a bearish technical signal but strong fundamentals including a 41.8% net income margin and consistent earnings beats. The stock faces resistance near $288, with support at $282. Recent developments include the completion of the Public Storage Canada acquisition and a $400 million senior notes offering in the Canadian market, signaling expansion efforts.
The outlook is mixed: analyst consensus targets $328.33 (14% upside), but technicals and some news highlight valuation concerns. Key risks include interest rate sensitivity and competitive pressures in the REIT sector. Earnings momentum and a 4.05% yield offer support, though investor caution is warranted amid bearish indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
